NEWS RELEASES

Search all of our news releases here.

Try these: Jeff GalvinC. David PauzaHIVFDAAmerican Gene Technologies

Angel investor Ride Wave Ventures has made its first investment in American Gene Technologies

American Gene Technologies® Attracts Investment from Ride Wave Ventures

Apr 22, 2022

AGT™ welcomes additional support of its HIV Cure clinical trial and broad gene therapy development platform American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, announced today that angel investor Ride Wave Ventures has made its first investment in the company.   Ride…

Read More
American Gene Technologies Launches The Cure Chronicles

American Gene Technologies® Launches “The Cure Chronicles” Video Series

Mar 30, 2022

“The Cure Chronicles” presents thoughtful conversations with people living with HIV, advocates, medical experts, policymakers, and others working toward ending the HIV epidemic. American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, has launched a video series showcasing compelling HIV community conversations: The…

Read More
American Gene Technologies thanks the State of Maryland for its commitment to supporting biotech research

American Gene Technologies® Applauds the State of Maryland for Supporting Biotech Investment

Mar 2, 2022

Maryland’s Biotechnology Investment Incentive Tax Credit (BIITC) program generates multiple benefits for the state American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, thanks the State of Maryland for its commitment to supporting biotech research through initiatives like the Biotechnology Investment Incentive Tax…

Read More
The independent Institutional Review Board (IRB) overseeing its clinical trial approved the company to proceed with analytic treatment interruption (ATI) to ultimately determine if AGT’s cell therapy can functionally cure HIV

American Gene Technologies® Advances Closer to Demonstrating a Potential Cure for HIV

Feb 24, 2022

HIV cure clinical trial data shows safety and efficacy of AGT™ gene therapy treatment, the company will begin withdrawing participants from antiretrovirals in Q2 to test potential functional cure American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that the independent…

Read More
Five participants were treated with AGT103-T and are stably engrafted with genetically modified cells

American Gene Technologies® HIV Clinical Trial Shows Blood Markers of Efficacy in Two More Patients

Feb 2, 2022

Data from a Total of Five Patients Demonstrates Critical Markers of the Company’s HIV Cure Gene & Cell Therapy American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, announced that it has reached another important milestone for its HIV cure program. Five participants were…

Read More
Dr. Drew Palin has been appointed as business and strategy advisor to Jeff Galvin, CEO

American Gene Technologies® Appoints Dr. Drew Palin as Business and Strategy Advisor to the CEO

Jan 5, 2022

Dr. Palin’s expertise in the intersection of business and technology strengthens AGT™ capability to bring patient solutions to the market. American Gene Technologies (AGT) announces the appointment of Dr. Drew Palin as business and strategy advisor to Jeff Galvin, CEO.   “I am excited to have…

Read More
American Gene Technologies announces that it has reached two important milestones for its HIV cure program

American Gene Technologies® HIV Clinical Trial Demonstrates Blood Markers of Efficacy

Dec 21, 2021

Data from the First Three Patients Shows Critical Markers of the HIV Cure Cell Therapy: Engraftment, Persistence, and Function of Infused Cells American Gene Technologies (AGT™), a clinical-stage biotechnology company working to cure HIV, announced that it has reached two important milestones for its HIV cure…

Read More
The independent Data Safety and Monitoring Board (DSMB) overseeing the trial of AGT’s HIV gene therapy found no serious adverse events (SAEs) from the treatment for the third patient and voted unanimously to allow AGT’s HIV cure program to continue at a faster pace

American Gene Technologies Passes Major Milestone in Potential HIV Cure Clinical Trial with Third Patient Showing No Serious Adverse Effects (SAEs)

Nov 9, 2021

American Gene Technologies (AGT), a clinical-stage biotechnology company, announced that the independent Data Safety and Monitoring Board (DSMB) overseeing the trial of AGT’s HIV gene therapy found no serious adverse events (SAEs) from the treatment for the third patient and voted unanimously to allow AGT’s HIV…

Read More
Dr. Marcus A. Conant, a leading dermatologist in the U.S. and one of the first physicians to diagnose and treat AIDS, has been appointed as special advisor to AGT CEO Jeff Galvin

American Gene Technologies Appoints Dr. Marcus A. Conant as Special Advisor to the CEO

Oct 1, 2021

Dr. Conant, one of the first HIV/AIDS treatment pioneers, strengthens AGT’s capacity to progress toward a functional cure October 01, 2021 13:25 ET | Source:  American Gene Technologies American Gene Technologies (AGT) announces the appointment of Dr. Marcus A. Conant, a leading dermatologist in the U.S. and…

Read More
The independent Data Safety and Monitoring Board (DSMB) in charge of the trial safety found no serious adverse events (SAEs) from the treatment for the second patient and voted unanimously to allow AGT’s HIV cure program to continue without modification

American Gene Technologies HIV Cure Clinical Trial Shows Additional Progress with No Serious Adverse Events (SAEs)

Sep 23, 2021

American Gene Technologies (AGT), a clinical-stage biotechnology company, announced that the independent Data Safety and Monitoring Board (DSMB) in charge of the trial safety found no serious adverse events (SAEs) from the treatment for the second patient and voted unanimously to allow AGT’s HIV cure program to…

Read More

Subscribe to News Releases and News Updates

Subscribe to our news release and published article updates to be notified when we release new content!

Follow AGT on Social Media

AGT on Facebook

Tune in to Cell & Gene: The Podcast and hear Addimmune's Dr. Marcus Conant, a pioneer in HIV research, discuss our innovative cell therapy for HIV. He shares his vision for empowering patients and transforming HIV treatment. loom.ly/96TZ0jU#HIV #celltherapy #biotech ... See MoreSee Less
View on Facebook
M&A has been steady in 2024. We count 47 private & public deals to date totaling $53 billion. 15 have been >$1 billion with cancer, rare disease & cell therapies some of the areas of interest. ... See MoreSee Less
View on Facebook
AGT CEO, Jeff Galvin, had a chat with social media influencer and HIV advocate, Raif Derrazi, to discuss the latest updates on our AGT103-T clinical trials. Dive into the conversation as they shed light on the research and what lies ahead in our mission to find a cure for HIV! loom.ly/jAThqIU#HIV #hivcure #HIVresearch #clinicaltrials ... See MoreSee Less
View on Facebook
Can genetic evidence make drugs more effective? A new study in Nature suggests YES. Drug mechanisms with genetic support have a 2.6x higher chance of success. loom.ly/NxSxjXk#genetics #science #healthcare ... See MoreSee Less
View on Facebook